386 related articles for article (PubMed ID: 27825119)
1. Malignant ascites enhances migratory and invasive properties of ovarian cancer cells with membrane bound IL-6R in vitro.
Kim S; Gwak H; Kim HS; Kim B; Dhanasekaran DN; Song YS
Oncotarget; 2016 Dec; 7(50):83148-83159. PubMed ID: 27825119
[TBL] [Abstract][Full Text] [Related]
2. IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells.
Zhu X; Shen H; Yin X; Long L; Chen X; Feng F; Liu Y; Zhao P; Xu Y; Li M; Xu W; Li Y
Oncotarget; 2017 Jun; 8(24):39154-39166. PubMed ID: 28388577
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effects of interleukin-6 (IL-6)/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovary.
Yanaihara N; Hirata Y; Yamaguchi N; Noguchi Y; Saito M; Nagata C; Takakura S; Yamada K; Okamoto A
Mol Carcinog; 2016 May; 55(5):832-41. PubMed ID: 25856562
[TBL] [Abstract][Full Text] [Related]
4. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
[TBL] [Abstract][Full Text] [Related]
5. TGFβ signaling regulates epithelial-mesenchymal plasticity in ovarian cancer ascites-derived spheroids.
Rafehi S; Ramos Valdes Y; Bertrand M; McGee J; Préfontaine M; Sugimoto A; DiMattia GE; Shepherd TG
Endocr Relat Cancer; 2016 Mar; 23(3):147-59. PubMed ID: 26647384
[TBL] [Abstract][Full Text] [Related]
6. Role of the interleukin 6 receptor family in epithelial ovarian cancer and its clinical implications.
Kumar J; Ward AC
Biochim Biophys Acta; 2014 Apr; 1845(2):117-25. PubMed ID: 24388871
[TBL] [Abstract][Full Text] [Related]
7. Adipose Stromal Cells from Visceral and Subcutaneous Fat Facilitate Migration of Ovarian Cancer Cells via IL-6/JAK2/STAT3 Pathway.
Kim B; Kim HS; Kim S; Haegeman G; Tsang BK; Dhanasekaran DN; Song YS
Cancer Res Treat; 2017 Apr; 49(2):338-349. PubMed ID: 27456942
[TBL] [Abstract][Full Text] [Related]
8. Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas.
Colomiere M; Ward AC; Riley C; Trenerry MK; Cameron-Smith D; Findlay J; Ackland L; Ahmed N
Br J Cancer; 2009 Jan; 100(1):134-44. PubMed ID: 19088723
[TBL] [Abstract][Full Text] [Related]
9. Snail Driving Alternative Splicing of CD44 by ESRP1 Enhances Invasion and Migration in Epithelial Ovarian Cancer.
Chen L; Yao Y; Sun L; Zhou J; Miao M; Luo S; Deng G; Li J; Wang J; Tang J
Cell Physiol Biochem; 2017; 43(6):2489-2504. PubMed ID: 29131012
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor-induced ovarian carcinoma cell migration is associated with JAK2/STAT3 signals and changes in the abundance and localization of alpha6beta1 integrin.
Colomiere M; Findlay J; Ackland L; Ahmed N
Int J Biochem Cell Biol; 2009 May; 41(5):1034-45. PubMed ID: 18930836
[TBL] [Abstract][Full Text] [Related]
11. Emodin inhibits epithelial to mesenchymal transition in epithelial ovarian cancer cells by regulation of GSK-3β/β-catenin/ZEB1 signaling pathway.
Hu C; Dong T; Li R; Lu J; Wei X; Liu P
Oncol Rep; 2016 Apr; 35(4):2027-34. PubMed ID: 26820690
[TBL] [Abstract][Full Text] [Related]
12. Intratumoral interleukin-6 predicts ascites formation in patients with epithelial ovarian cancer: A potential tool for close monitoring.
Masoumi-Moghaddam S; Amini A; Wei AQ; Robertson G; Morris DL
J Ovarian Res; 2015 Aug; 8():58. PubMed ID: 26282935
[TBL] [Abstract][Full Text] [Related]
13. Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer.
Alberti C; Pinciroli P; Valeri B; Ferri R; Ditto A; Umezawa K; Sensi M; Canevari S; Tomassetti A
Oncogene; 2012 Sep; 31(37):4139-49. PubMed ID: 22158046
[TBL] [Abstract][Full Text] [Related]
14. Interleukin 6 receptor is an independent prognostic factor and a potential therapeutic target of ovarian cancer.
Isobe A; Sawada K; Kinose Y; Ohyagi-Hara C; Nakatsuka E; Makino H; Ogura T; Mizuno T; Suzuki N; Morii E; Nakamura K; Sawada I; Toda A; Hashimoto K; Mabuchi S; Ohta T; Morishige K; Kurachi H; Kimura T
PLoS One; 2015; 10(2):e0118080. PubMed ID: 25658637
[TBL] [Abstract][Full Text] [Related]
15. Granulocyte colony-stimulating factor receptor signalling via Janus kinase 2/signal transducer and activator of transcription 3 in ovarian cancer.
Kumar J; Fraser FW; Riley C; Ahmed N; McCulloch DR; Ward AC
Br J Cancer; 2014 Jan; 110(1):133-45. PubMed ID: 24220695
[TBL] [Abstract][Full Text] [Related]
16. Tissue factor-factor VIIa complex induces epithelial ovarian cancer cell invasion and metastasis through a monocytes-dependent mechanism.
Ma Z; Zhang T; Wang R; Cheng Z; Xu H; Li W; Wang Y; Wang X
Int J Gynecol Cancer; 2011 May; 21(4):616-24. PubMed ID: 21543928
[TBL] [Abstract][Full Text] [Related]
17. Lysophosphatidic acid induces STAT3 phosphorylation and ovarian cancer cell motility: their inhibition by curcumin.
Seo JH; Jeong KJ; Oh WJ; Sul HJ; Sohn JS; Kim YK; Cho DY; Kang JK; Park CG; Lee HY
Cancer Lett; 2010 Feb; 288(1):50-6. PubMed ID: 19647363
[TBL] [Abstract][Full Text] [Related]
18. MiR-373 targeting of the Rab22a oncogene suppresses tumor invasion and metastasis in ovarian cancer.
Zhang Y; Zhao FJ; Chen LL; Wang LQ; Nephew KP; Wu YL; Zhang S
Oncotarget; 2014 Dec; 5(23):12291-303. PubMed ID: 25460499
[TBL] [Abstract][Full Text] [Related]
19. IL-6/IL-6R pathway is a therapeutic target in chemoresistant ovarian cancer.
Yousefi H; Momeny M; Ghaffari SH; Parsanejad N; Poursheikhani A; Javadikooshesh S; Zarrinrad G; Esmaeili F; Alishahi Z; Sabourinejad Z; Sankanian G; Shamsaiegahkani S; Bashash D; Shahsavani N; Tavakkoly-Bazzaz J; Alimoghaddam K; Ghavamzadeh A
Tumori; 2019 Feb; 105(1):84-91. PubMed ID: 30021477
[TBL] [Abstract][Full Text] [Related]
20. Celecoxib inhibits interleukin-6/interleukin-6 receptor-induced JAK2/STAT3 phosphorylation in human hepatocellular carcinoma cells.
Liu Y; Liu A; Li H; Li C; Lin J
Cancer Prev Res (Phila); 2011 Aug; 4(8):1296-305. PubMed ID: 21490132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
